LIB Therapeutics

artificial intelligence AI machine learning MI data
Biotech

Exelixis dips into the AI game, LIB cashes in on PCSK9

Exelixis is diving into AI drug development in a licensing deal with Insilico, while LIB Therapeutics is cashing in after a second phase 2 victory.
Max Bayer Sep 12, 2023 11:00am
An artists depiction of a heart with a clogged artery

LIB's cholesterol-busting drug hits goal in 2nd phase 3 trial

Aug 29, 2023 6:30am